Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal
- PMID: 17132097
- DOI: 10.1515/BC.2006.190
Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal
Abstract
Endothelial NO synthase (eNOS) is the predominant enzyme responsible for vascular NO synthesis. A functional eNOS transfers electrons from NADPH to its heme center, where L-arginine is oxidized to L-citrulline and NO. Common conditions predisposing to atherosclerosis, such as hypertension, hypercholesterolemia, diabetes mellitus and smoking, are associated with enhanced production of reactive oxygen species (ROS) and reduced amounts of bioactive NO in the vessel wall. NADPH oxidases represent major sources of ROS in cardiovascular pathophysiology. NADPH oxidase-derived superoxide avidly interacts with eNOS-derived NO to form peroxynitrite (ONOO(-)), which oxidizes the essential NOS cofactor (6R-)5,6,7,8-tetrahydrobiopterin (BH(4)). As a consequence, oxygen reduction uncouples from NO synthesis, thereby rendering NOS to a superoxide-producing pro-atherosclerotic enzyme. Supplementation with BH(4) corrects eNOS dysfunction in several animal models and in patients. Administration of high local doses of the antioxidant L-ascorbic acid (vitamin C) improves endothelial function, whereas large-scale clinical trials do not support a strong role for oral vitamin C and/or E in reducing cardiovascular disease. Statins, angiotensin-converting enzyme inhibitors and AT1 receptor blockers have the potential of reducing vascular oxidative stress. Finally, novel approaches are being tested to block pathways leading to oxidative stress (e.g. protein kinase C) or to upregulate antioxidant enzymes.
Similar articles
-
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?Pharmacol Ther. 2013 Dec;140(3):239-57. doi: 10.1016/j.pharmthera.2013.07.004. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859953 Review.
-
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Br J Pharmacol. 2011 Sep;164(2):213-23. doi: 10.1111/j.1476-5381.2010.01196.x. Br J Pharmacol. 2011. PMID: 21198553 Free PMC article. Review.
-
Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling.J Pharmacol Exp Ther. 2008 May;325(2):370-9. doi: 10.1124/jpet.107.128009. Epub 2008 Feb 5. J Pharmacol Exp Ther. 2008. PMID: 18252813
-
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes.Diabetes. 2007 Mar;56(3):666-74. doi: 10.2337/db06-0699. Diabetes. 2007. PMID: 17327434
-
Endothelial nitric oxide synthase in vascular disease: from marvel to menace.Circulation. 2006 Apr 4;113(13):1708-14. doi: 10.1161/CIRCULATIONAHA.105.602532. Circulation. 2006. PMID: 16585403 Review.
Cited by
-
Insights into the relationship between serum uric acid and pulmonary hypertension (Review).Mol Med Rep. 2024 Jan;29(1):10. doi: 10.3892/mmr.2023.13133. Epub 2023 Nov 24. Mol Med Rep. 2024. PMID: 37997855 Free PMC article. Review.
-
Cross-Regulation of the Cellular Redox System, Oxygen, and Sphingolipid Signalling.Metabolites. 2023 Mar 14;13(3):426. doi: 10.3390/metabo13030426. Metabolites. 2023. PMID: 36984866 Free PMC article. Review.
-
Oxidative Stress Induced by 30 Days of Mercury Exposure Accelerates Hypertension Development in Prehypertensive Young SHRs.Cardiovasc Toxicol. 2022 Dec;22(12):929-939. doi: 10.1007/s12012-022-09769-z. Epub 2022 Nov 2. Cardiovasc Toxicol. 2022. PMID: 36324000
-
Venous endothelial function in cardiovascular disease.Biosci Rep. 2022 Nov 30;42(11):BSR20220285. doi: 10.1042/BSR20220285. Biosci Rep. 2022. PMID: 36281946 Free PMC article.
-
Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data.Int J Mol Sci. 2022 Jun 30;23(13):7261. doi: 10.3390/ijms23137261. Int J Mol Sci. 2022. PMID: 35806265 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials